Track topics on Twitter Track topics that are important to you
UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in Feb...
UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO®, a treatment for early stage Parkinson's disease. NEUPRO (rotigotine) i...
* Announces first presentation of data from Neupro (rotigotine transdermal patch) phase 3 study in China at international congress
UCB Group (Euronext:UCB) gained EUR 4.29 to EUR 75.81 on Wednesday after reporting 3Q15 earnings and raising its guidance for 2015. The company raised its revenue guidance to EUR 3.75 billion ($4.14 b...